215 First Street
Decibel Therapeutics is a hearing company focused on discovering and developing new therapies to protect, repair and restore hearing. By combining recent innovations in hearing science with leading diagnostic tools, biological insights, modeling and therapeutic delivery techniques, Decibel is pioneering a comprehensive approach to define the underlying biological causes of hearing loss and develop a pipeline of breakthrough therapies targeted to specific indications and populations. Founded by the world’s preeminent experts in hearing loss, Decibel Therapeutics was launched in 2015 by Third Rock Ventures and is headquartered in Cambridge, Mass.
President and CEO: Steven Holtzman
CMO: Leslie Shinobu, M.D., Ph.D.
Vice President, Pharmacology: Ada Silos-Santiago, Ph.D.
October 15, 2015: $52 Million Series A From GlaxoSmithKline, SR One and Third Rock Ventures.